Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Insufficient Metabolic Control”

358 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 358 results

Not applicableStudy completedNCT04467268
What this trial is testing

Sleep Extension for Metabolic Health

Who this might be right for
Short Sleep
Loughborough University 18
Testing effectiveness (Phase 2)Study completedNCT01193218
What this trial is testing

Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 547
Not applicableWithdrawnNCT06692153
What this trial is testing

Embecta AID System in Adults With Type 2 Diabetes

Who this might be right for
Type 2 DiabetesType 2 Diabetes Mellitus (T2DM)Type 2 DM+4 more
Embecta Corp.
Large-scale testing (Phase 3)Study completedNCT01392677
What this trial is testing

Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea

Who this might be right for
Type 2 Diabetes MellitusHigh HbA1c LevelInadequate Glycaemic Control
AstraZeneca 311
Large-scale testing (Phase 3)Study completedNCT01214239
What this trial is testing

Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 300
Large-scale testing (Phase 3)Study completedNCT01210001
What this trial is testing

Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 499
Large-scale testing (Phase 3)Study completedNCT00683657
What this trial is testing

Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone

Who this might be right for
Type 2 Diabetes
AstraZeneca 93
Large-scale testing (Phase 3)Study completedNCT02577016
What this trial is testing

Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)

Who this might be right for
Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC 141
Testing effectiveness (Phase 2)Study completedNCT01096667
What this trial is testing

Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)

Who this might be right for
Diabetes Mellitus, Type 2Hypertension
Merck Sharp & Dohme LLC 194
Large-scale testing (Phase 3)Ended earlyNCT03608358
What this trial is testing

Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin

Who this might be right for
Type 2 Diabetes Mellitus
AstraZeneca 41
Large-scale testing (Phase 3)Study completedNCT00432276
What this trial is testing

Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus

Who this might be right for
Diabetes Mellitus
Takeda 803
Large-scale testing (Phase 3)Study completedNCT00313313
What this trial is testing

Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas

Who this might be right for
Diabetes
AstraZeneca 768
Large-scale testing (Phase 3)Study completedNCT02229396
What this trial is testing

Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo

Who this might be right for
Diabetes Mellitus
AstraZeneca 695
Large-scale testing (Phase 3)Study completedNCT03066830
What this trial is testing

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin

Who this might be right for
Type 2 Diabetes Mellitus
Lexicon Pharmaceuticals 507
Large-scale testing (Phase 3)Study completedNCT00147758
What this trial is testing

WelChol® and Sulfonylurea in Treating Patients With Type 2 Diabetes

Who this might be right for
Type 2 Diabetes
Daiichi Sankyo 400
Post-approval studies (Phase 4)Study completedNCT02471404
What this trial is testing

Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea

Who this might be right for
Type 2 Diabetes MellitusInadequate Glycaemic Control
AstraZeneca 939
Post-approval studies (Phase 4)Study completedNCT00941148
What this trial is testing

Beta-Cell Function of Insulin Glargine Compared to Neutral Protamine Hagedorn (NPH) Insuline and to Insulin Detemir in Combination With Metformin

Who this might be right for
Type 2 Diabetic PatientsInsufficient Metabolic ControlOAD Treatment
ikfe-CRO GmbH 30
Post-approval studies (Phase 4)Study completedNCT01438814
What this trial is testing

Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 689
Large-scale testing (Phase 3)Study completedNCT00622284
What this trial is testing

Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 1,560
Large-scale testing (Phase 3)Ended earlyNCT01678820
What this trial is testing

The Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)

Who this might be right for
Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC 299
Next Page